On May 1, 2025, Fortrea Holdings Inc. announced its recognition as a 'Leader' for pharmacovigilance (PV) operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix® Assessment 2025. Fortrea achieved a top position in both pre- and post-approval PV operations.
This assessment, based on market impact, vision, and capability, highlights Fortrea's global end-to-end safety solutions that span the entire product life cycle. Mark Morais, Chief Operations Officer, emphasized the company's profound commitment to patients and its 'first-time-right' approach.
The Everest Group report specifically noted Fortrea's strengths in scientific depth, scalability, and global reach, along with its multidisciplinary collaboration model and technology-led innovation. This external validation reinforces Fortrea's competitive standing and expertise in a critical service area within the CRO industry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.